Effects of Empagliflozin‐Induced Glycosuria on Weight Gain, Food Intake and Metabolic Indicators in Mice Fed a High‐Fat Diet
Endocrinology, Diabetes & Metabolism · 2024
DOI: 10.1002/edm2.475 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, Diabetes & Metabolism, 2024. Verfasst von Anh T Nguyen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Fred Wilson School of Pharmacy, High Point University, High Point, North Carolina, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Glycosuria, Benzhydryl Compounds. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: High Point University.
Abstract (Originalsprache)
Background
Sodium glucose‐linked transporter 2 (SGLT2) inhibitors promote glucose, and therefore calorie, excretion in the urine. Patients taking SGLT2 inhibitors typically experience mild weight loss, but the amount of weight loss falls short of what is expected based on caloric loss. Understanding the mechanisms responsible for this weight loss discrepancy is imperative, as strategies to improve weight loss could markedly improve type 2 diabetes management and overall metabolic health.
Methods
Two mouse models of diet‐induced obesity were administered the SGLT2 inhibitor empagliflozin in the food for 3 months. Urine glucose excretion, body weight, food intake and activity levels were monitored. In addition, serum hormone measurements were taken, and gene expression analyses were conducted.
Results
In both mouse models, mice receiving empagliflozin gained the same amount of body weight as their diet‐matched controls despite marked glucose loss in the urine. No changes in food intake, serum ghrelin concentrations or activity levels were observed, but serum levels of fibroblast growth factor 21 (FGF21) decreased after treatment. A decrease in the levels of deiodinase 2 (Dio2) was also observed in the white adipose tissue, a primary target tissue of FGF21.
Conclusion
These findings suggest that compensatory metabolic adaptations, other than increased food intake or decreased physical activity, occur in response to SGLT2 inhibitor‐induced glycosuria that combats weight loss, and that reductions in FGF21, along with subsequent reductions in peripheral Dio2, may play a role.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fred Wilson School of Pharmacy, High Point University, High Point, North Carolina, USA.
ORCID-Profile: Sara M McMillin
Förderung
- High Point University
Zitieren
APA
Nguyen, A. T., Amigo, Z., McDuffie, K., MacQueen, V. C., Bell, L. D., Truong, L. K., Batchi, G., & McMillin, S. M. (2024). Effects of Empagliflozin‐Induced Glycosuria on Weight Gain, Food Intake and Metabolic Indicators in Mice Fed a High‐Fat Diet. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.475
Vancouver
Nguyen AT, Amigo Z, McDuffie K, MacQueen VC, Bell LD, Truong LK, et al. Effects of Empagliflozin‐Induced Glycosuria on Weight Gain, Food Intake and Metabolic Indicators in Mice Fed a High‐Fat Diet. Endocrinology, Diabetes & Metabolism. 2024. doi:10.1002/edm2.475
BibTeX
@article{Nguyen2024,
author = {Nguyen, Anh T and Amigo, Zachary and McDuffie, Kathleen and MacQueen, Victoria C and Bell, Lane D and Truong, Lan K and Batchi, Gloria and McMillin, Sara M},
title = {Effects of Empagliflozin‐Induced Glycosuria on Weight Gain, Food Intake and Metabolic Indicators in Mice Fed a High‐Fat Diet},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2024},
doi = {10.1002/edm2.475}
}
EUVIMED